Prot #19774: A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of the combination of rogaratinib and copanlisib in patients with FGFR-positive, local

Project: Research project

Project Details

StatusActive
Effective start/end date10/18/185/19/21

Funding

  • Bayer HealthCare Pharmaceuticals, Inc. (Prot #19774)